The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

The scientific community is reeling in the wake of the Trump administration’s announcement that it will dramatically cut support for “indirect costs ... novel antibody drugs from scratch ...

Trials in China usually recruit patients faster than in the west because of the country’s large pool of people who have not ...

Figure 1: Antibody design to improve homogeneity ... Thus, decreasing costs is an important part of drug development. The IgG-based biotherapeutic agents that have been approved in the past ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...

Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 million Preliminary Q4 2024 total operating costs and expenses ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

The European Commission (EC) has approved catumaxomab, making it the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.